The recently published long-term results of the SABR-COMET phase II trial have further invigorated treatment options for patients with oligometastatic cancer.1 The early results of the SABR-COMET trial published in […] Read more
Megan Daly The standard of care for fit patients with unresectable, locally advanced (LA-) NSCLC is concurrent chemoradiation (CRT) followed by consolidation durvalumab. However, thoracic radiation (RT) for lung cancer […] Read more
By Arya Amini, MD, and Chad G. Rusthoven, MD Posted: August 19, 2020 Approximately 10% of patients diagnosed with metastatic NSCLC present with brain metastases, and another 30% develop brain […] Read more
By Elizabeth Gore, MD Posted: May 27, 2019 IN REFERENCE TO: De Ruysscher D, Dingemans AC, Praag J, et al. Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell […] Read more
By John Armstrong, MD, FRCPI, DABR, FFRRCSI Posted: December 2018 RTOG 0214, a phase III randomized trial, is the biggest trial to date testing prophylactic cranial irradiation (PCI) in locally […] Read more
By Shalini K. Vinod, MBBS, MD Posted: October 2018 The standard of care for patients with inoperable stage III NSCLC is curative radiotherapy and concurrent chemotherapy.1 However, there are numerous […] Read more
Posted: October 2018 Patients with stage III or more advanced lung cancer tend to be older and less healthy than patients with other stage III cancers. Because of this, selection […] Read more
By Leah Lawrence Posted: June 2018 The use of trimodality therapy—the combination of chemoradiotherapy followed by surgery—remains controversial for patients with locally advanced cN2-N3 NSCLC. According to the National Comprehensive […] Read more
By Pranshu Mohindra, MD, MBBS, DABR®, Lecia Sequist, MD, and Laurie E. Gaspar, MD, MBA Posted: December 2017 Since the initial approval of erlotinib, an oral tyrosine kinase inhibitor (TKI), […] Read more
By Suresh Senan, MRCP, FRCR, PhD Posted: December 2017 Improved delivery of radiotherapy has contributed to the recent changes in guidelines for patients with lung cancer. The clinical impact of […] Read more